Redx Pharma's (LON:REDX) chief medical officer Andrew Saunders recaps on its lead clinical programme RXC004. He says clinical evaluation of the drug in patients with advanced solid tumours in a phase 1 study is expected to complete in the second half of this year however recruitment into the trial has been paused due to COVID-19. Saunders adds that, once they're able to, the plans are to initiate Phase 2 studies before the end of the year in both mono-therapy as well as studying the combination of RXC004 with a checkpoint inhibitor.
10 Jun 20